Lung Cancer Surgery

Introduction

Being told that surgery is part of your lung cancer treatment is a major moment. You may have learned about the cancer after months of cough or breathlessness, after coughing up blood, or after a scan picked up an unexpected nodule. Now your team has explained that an operation to remove part of the lung is being recommended, and you are trying to understand what that means.

This guide is for patients and families who already have a lung cancer diagnosis and are planning the surgical phase of treatment. It explains what lung cancer surgery is, who it is offered to, the different operations and approaches surgeons use, how to prepare, what the hospital stay and recovery look like, the risks involved, and how surgery fits together with chemotherapy, radiation, targeted therapy, and immunotherapy.

The medical landscape for lung cancer has changed substantially in the last decade. Minimally invasive techniques — video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery — are now used for most early-stage tumours where the anatomy allows. Lung-sparing operations such as segmentectomy have become more common for small tumours. And surgery is increasingly combined with drug treatment before or after the operation. Understanding where your operation fits within this picture makes the conversations with your surgeon and oncologist much easier.

What Is Lung Cancer Surgery?

Lung cancer surgery is an operation to remove a cancerous tumour from the lung, along with a margin of surrounding healthy tissue and the lymph nodes that drain that part of the lung. The aim, when surgery is being offered with curative intent, is what surgeons call a complete resection or “R0 resection” — removing all visible and microscopic cancer so that the cut edges of the tissue are clear under the microscope.

Surgery is most relevant for non-small cell lung cancer (NSCLC), which makes up the large majority of lung cancers and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. For early-stage NSCLC, current guidelines from bodies such as the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) describe surgery as the cornerstone of curative treatment.

Small cell lung cancer (SCLC) behaves differently. It tends to spread early, and treatment usually centres on chemotherapy, immunotherapy, and radiation rather than surgery. Surgery is offered only in a small number of very early SCLC cases.

Other situations where lung surgery is used in cancer care include removing isolated metastases from other cancers that have spread to the lung (a separate situation called pulmonary metastasectomy) and removing tumours of the airways or chest wall that involve the lung.

The amount of lung tissue removed depends on the size and position of the tumour. The surgeon’s aim is always to take out all of the cancer while leaving behind as much healthy, functioning lung as safely possible.

Why Lung Cancer Surgery Is Performed

Surgery serves several purposes in lung cancer care, and your team may be aiming at more than one of them.

Curative removal of the tumour. In early-stage disease, surgery offers the best chance of long-term cure. Removing the tumour completely, with clear margins and an adequate lymph node assessment, is the single most powerful step in eliminating the cancer.

Accurate staging. Even with modern CT and PET-CT scanning, the final and most reliable stage of a lung cancer is established by examining the tumour and the lymph nodes that have been removed. This information shapes whether chemotherapy, immunotherapy, or radiation is added after surgery.

Local control in locally advanced disease. In selected stage IIIA cases, surgery may be combined with chemotherapy and/or immunotherapy given before the operation (neoadjuvant therapy) to shrink the tumour and improve the chance of complete removal.

Whether surgery is the right treatment is a clinical decision made by a multidisciplinary tumour board — typically a thoracic surgeon, medical oncologist, radiation oncologist, pulmonologist, radiologist, and pathologist who review your case together. They consider three broad questions.

Is the cancer surgically removable?

This depends on the stage and location of the tumour. Surgery is commonly offered for:

• Stage I NSCLC (small tumour, no lymph node spread)
• Stage II NSCLC (larger tumour, or limited spread to nearby lymph nodes)
• Selected stage IIIA NSCLC, usually combined with chemotherapy and/or immunotherapy before or after surgery
• Very early-stage small cell lung cancer in carefully chosen patients

Surgery is generally not offered when the cancer has spread to distant organs, to lymph nodes on the opposite side of the chest, or to multiple mediastinal nodes that cannot be cleared by an operation. In those situations, drug treatment and radiation are usually the main approaches.

Can your lungs and heart cope with the operation?

Removing part of a lung permanently reduces the total amount of lung tissue available for breathing. Before recommending surgery, your team will measure your lung function and estimate how much will be left after the operation. Tests typically include:

• Spirometry — measuring how much air you can blow out
• Diffusing capacity (DLCO) — measuring how well oxygen passes from the lungs into the blood
• Cardiac evaluation — an ECG, often with an echocardiogram, and sometimes a stress test, particularly if you have heart disease or risk factors
• Exercise testing — such as a stair climb or, in more complex cases, a formal cardiopulmonary exercise test

If lung function is borderline, your surgeon may favour a smaller, lung-sparing operation (segmentectomy or wedge resection) rather than removing a whole lobe.

Are you medically fit enough?

Other health conditions — uncontrolled heart disease, severe COPD, frailty, significant kidney or liver disease — influence the risk of surgery. The team weighs the benefit of removing the cancer against the risk of complications. For some patients, non-surgical curative options such as stereotactic body radiation therapy may be considered instead.

Alternatives to Surgery

For early-stage lung cancer, surgery is the treatment most cancer societies describe as offering the best chance of cure. But it is not the only option, and for some patients it is not the right one. Understanding the alternatives helps you have a clearer conversation with your team.

Stereotactic body radiation therapy (SBRT)

SBRT delivers high doses of precisely focused radiation to the tumour in a small number of sessions. It is commonly offered to patients with early-stage NSCLC who cannot have surgery because of poor lung function, other medical problems, or personal choice. Outcomes for very small, peripherally located tumours are good, though long-term comparisons with surgery in fit patients have shown a survival advantage for surgery in most studies.

Radiofrequency or microwave ablation

Image-guided needle treatments that heat and destroy small lung tumours. These are used in selected patients who are not surgical candidates and have a single small tumour.

Systemic therapy alone

For locally advanced or metastatic disease, the main treatments are chemotherapy, immunotherapy (drugs that help the immune system attack cancer), and targeted therapy (drugs aimed at specific genetic changes such as EGFR, ALK, ROS1, or KRAS mutations). Surgery may not add benefit in these situations.

Chemoradiotherapy

For stage III disease that cannot be operated on, combined chemotherapy and radiation, often followed by immunotherapy, is the standard approach described by major guidelines.

Whether any of these alternatives is appropriate is a clinical decision that depends on the stage, the genetic profile of the tumour, your lung and heart function, and your preferences.

Types of Lung Cancer Surgery

Lobectomy

The lungs are divided into lobes — three on the right and two on the left. A lobectomy removes the entire lobe that contains the tumour. For many years, lobectomy has been the standard operation for early-stage NSCLC because it reliably removes the tumour along with the lymphatic drainage of that lobe. Most patients have enough remaining lung tissue to maintain a good quality of life afterwards.

Segmentectomy

Each lobe is divided into smaller anatomical units called segments. A segmentectomy removes only the segment containing the tumour, preserving more lung tissue than a lobectomy. Recent large clinical trials have shown that for carefully selected small (2 cm or less), peripheral, early-stage NSCLC, segmentectomy gives outcomes comparable to lobectomy while preserving more lung function. Major guidelines now describe segmentectomy as an accepted option in these specific situations.

Wedge resection

A smaller, non-anatomic removal of a wedge-shaped piece of lung containing the tumour. Wedge resection takes out less tissue than a segmentectomy and is mainly used for very small tumours, for diagnostic biopsy when the diagnosis is uncertain, and for patients whose lung function will not tolerate a larger operation. Because it removes fewer lymph nodes and a smaller margin, the risk of cancer returning at the same site can be higher than with anatomic resections.

Pneumonectomy

Removal of an entire lung. Pneumonectomy is needed when the tumour involves the main airway (the main bronchus), crosses between lobes, or invades central blood vessels in a way that cannot be addressed with a smaller operation. It is a larger operation with a longer recovery and a permanent, significant reduction in lung capacity. Surgeons generally avoid pneumonectomy whenever a lobectomy or sleeve resection can achieve a complete removal.

Sleeve resection

A specialised lung-sparing operation in which a section of airway containing the tumour is removed and the cut ends of the airway are sewn back together — like removing a damaged piece of a sleeve and rejoining the cuff to the rest of the sleeve. Sleeve resection allows the remaining lobes to be preserved instead of removing the whole lung. It is technically demanding and offered in experienced centres.

Lymph node dissection

Whichever resection is performed, the surgeon also removes lymph nodes from defined areas of the chest. This is called a mediastinal lymph node dissection or sampling. It is not optional; it provides essential staging information and helps reduce the risk of cancer coming back.

Surgical Approaches

Open thoracotomy

The traditional approach. The surgeon makes a curved incision along the side of the chest, between the ribs, often around 10–20 cm long. The ribs are gently spread to give direct access to the lung. Open surgery remains important for large or complex tumours, for tumours that involve the chest wall or central blood vessels, for sleeve resections in some centres, and when prior surgery or infection has caused dense scarring inside the chest.

Recovery from a thoracotomy tends to be more painful and slower than from minimally invasive approaches because the chest wall and rib joints have been disturbed more.

Video-assisted thoracoscopic surgery (VATS)

VATS is a minimally invasive (“keyhole”) approach. The surgeon makes a small number of small incisions, usually 1–4 cm each, and operates using a video camera (thoracoscope) and long, thin instruments inserted through these openings. The same operations — wedge resection, segmentectomy, lobectomy — can be performed through VATS in suitable patients.

Compared with open thoracotomy, VATS has been shown in many studies to reduce post-operative pain, shorten hospital stay, lower the rate of certain complications, and allow a faster return to normal activity, while achieving the same oncological results in early-stage disease. Most early-stage lung cancers in experienced centres are now operated through VATS.

Robotic-assisted thoracic surgery

Robotic surgery is also minimally invasive. The surgeon sits at a console and controls robotic arms that hold the instruments and camera. The robotic system provides a magnified three-dimensional view of the inside of the chest and instruments that can move in more directions than a human wrist.

For lung cancer, robotic surgery is used to perform the same operations as VATS. Surgeons who use it often describe advantages for fine dissection around blood vessels and for thorough lymph node clearance. Studies comparing VATS and robotic approaches generally show similar cancer outcomes and recovery; the choice often depends on the experience of the surgical team and the equipment available.

Open, VATS, and robotic approaches are all legitimate ways to perform lung cancer surgery. Which is suitable depends on the tumour, your anatomy, prior treatments, and the surgeon’s experience.

Preparing for Lung Cancer Surgery

Preparation begins as soon as surgery is recommended. The goals are to confirm staging, optimise your fitness, and plan the operation in detail.

Staging and imaging

• High-resolution CT scan of the chest and upper abdomen
• PET-CT scan to look for spread to lymph nodes and distant organs
• MRI of the brain in many cases, because lung cancer can spread to the brain silently
• Bronchoscopy — passing a thin camera into the airways to assess the tumour and sometimes biopsy it
• Endobronchial ultrasound (EBUS) — combined with bronchoscopy, this allows lymph nodes deep inside the chest to be sampled with a needle to confirm whether they contain cancer

Tissue diagnosis and molecular testing

A biopsy confirms the type of lung cancer. For non-small cell cancers, the tissue is usually tested for genetic changes (such as EGFR, ALK, ROS1, KRAS, BRAF) and for a marker called PD-L1. These results affect whether targeted therapy or immunotherapy will be added before or after surgery.

Fitness and lung function

Lung function tests, cardiac assessment, and blood tests are performed as described earlier. Your team may also ask about exercise capacity and walking distance.

Stopping smoking

If you smoke, stopping before surgery — ideally for at least four to eight weeks — has been shown to significantly reduce the risk of post-operative chest complications, including pneumonia and prolonged air leaks. Your team can help with nicotine replacement and counselling.

Prehabilitation

Many centres now offer a structured programme of breathing exercises, walking, and nutritional support in the weeks before surgery. Even simple measures — daily walking, breathing exercises with an incentive spirometer, eating enough protein — help recovery.

Reviewing medications

You will be asked about all medicines, including over-the-counter drugs and supplements. Blood thinners, some diabetes drugs, and certain herbal supplements may need to be paused before surgery. Do not stop any medicine without checking with the team first.

Consent and questions

Before surgery you will sign a consent form. This is a good time to confirm the planned operation (which lobe, which approach), the expected hospital stay, what to expect during recovery, and the main risks. Bringing written questions and a family member helps.

What Happens During Lung Cancer Surgery

On the day of surgery, you will not have eaten for several hours. You will meet the surgical and anaesthesia teams again, and any final questions can be answered.

Anaesthesia

Lung cancer surgery is performed under general anaesthesia. A special double-lumen breathing tube is placed so that the anaesthetist can deflate the lung being operated on while the other lung continues to provide oxygen — a technique called one-lung ventilation. An epidural or nerve block is often placed at the start to help with pain control after surgery.

The operation

You are positioned on your side. The chosen approach — open, VATS, or robotic — determines the size and number of incisions.

The surgeon identifies the tumour, then carefully separates and divides the blood vessels and airway supplying the part of the lung to be removed. The diseased portion is taken out through one of the incisions, often inside a protective bag to avoid spilling tumour cells. Lymph nodes from several stations within the chest are also removed and labelled for the pathologist.

Before closing, the surgeon checks for air leaks by inflating the remaining lung under saline and watching for bubbles. One or two chest drains (tubes) are placed to remove air and fluid in the days after surgery. The incisions are then closed.

Operating time varies. A straightforward VATS lobectomy may take around two to three hours; a complex sleeve resection or pneumonectomy can take longer. Time in the operating room is longer than the surgery itself because of anaesthesia preparation, positioning, and recovery.

In the immediate recovery area

You wake up in a recovery room or intensive care unit. You will have:

• An oxygen mask or nasal prongs
• One or two chest drains attached to a sealed drainage system
• A drip in a vein for fluids and medicines
• A urinary catheter, usually for the first day or two
• An epidural or other pain-relief system

You may have a sore throat from the breathing tube and discomfort at the incisions, especially when breathing deeply or coughing. Both are expected and managed with pain relief.

Recovery and Healing

In hospital

Typical hospital stay is around three to seven days for a VATS or robotic lobectomy, often longer after a pneumonectomy or a complex open operation. Key elements of in-hospital recovery include:

• Breathing exercises. A physiotherapist will see you on the first day. Using an incentive spirometer and doing deep-breathing and coughing exercises every hour while awake helps the remaining lung re-expand fully and reduces the risk of pneumonia.
• Early mobilisation. Sitting out of bed, then walking with help, usually starts on the first day after surgery. Movement reduces the risk of blood clots and pneumonia and helps the bowels recover.
• Pain control. A combination of an epidural or nerve block, paracetamol, and other medicines is used. Good pain control is essential because it allows you to breathe deeply and walk.
• Chest drain management. The drains stay in until the lung has fully re-expanded and any air leak has stopped. They are removed at the bedside, usually within a few days.
• Eating and drinking. Most patients can drink the day of surgery and eat the following day.

At home

Once home, recovery continues over several weeks. General milestones include:

• Weeks 1–2. Incisions are healing. You may feel tired, short of breath on exertion, and have discomfort around the incisions. Daily walking and breathing exercises are encouraged.
• Weeks 3–4. Most people are doing light household activities, walking further, and reducing pain medicines.
• Weeks 6–8. Many patients are back to most routine activities. Driving is usually possible once you are off strong pain medicines and can move comfortably enough to perform an emergency stop. Your surgeon will give specific advice.
• Three to six months. Breathing capacity continues to improve as the remaining lung tissue adapts. Energy levels usually return to a new normal in this window.

Recovery from open thoracotomy is generally slower than from VATS or robotic surgery, particularly in the first few weeks. Recovery from pneumonectomy involves a longer adjustment to reduced lung capacity, and breathlessness on exertion may be more noticeable.

Numbness or tingling along the incision, intermittent twinges in the chest wall, and occasional aches can persist for months and sometimes longer. A small number of patients develop longer-lasting post-thoracotomy pain that needs specific treatment.

Risks and Complications

Lung cancer surgery is major surgery. Modern techniques, anaesthesia, and post-operative care have made it much safer than in previous decades, but risks remain and should be discussed openly with your team.

Common or important complications include:

• Prolonged air leak. Air leaking from the cut surface of the lung is the most common reason for a longer hospital stay. Most leaks settle on their own with the chest drain in place.
• Pneumonia and other chest infections. Reduced ability to cough, areas of collapsed lung, and the effects of anaesthesia all raise this risk. Breathing exercises, early walking, and stopping smoking before surgery reduce it.
• Atrial fibrillation — an irregular heart rhythm — develops in a meaningful proportion of patients after lung surgery, particularly older patients. It is usually temporary and treated with medicines.
• Bleeding during or after surgery, occasionally requiring transfusion or, rarely, a return to the operating room.
• Blood clots in the legs or lungs (deep vein thrombosis, pulmonary embolism). Preventive measures include leg compression devices, early walking, and blood-thinner injections.
• Wound infection at the incision sites, usually treated with antibiotics.
• Reduced lung capacity. Some lasting reduction in lung function is expected and depends on how much tissue is removed. Most patients adapt well, particularly after lobectomy or smaller resections.
• Persistent pain at the surgical site, particularly after open thoracotomy.
• Less common but serious complications include bronchopleural fistula (a connection between an airway and the chest cavity), empyema (infection of the chest cavity), injury to nearby nerves (such as the recurrent laryngeal nerve, causing voice changes), and, rarely, mortality. Risk of death from lung cancer surgery in experienced centres is low, with higher risk after pneumonectomy than after smaller resections.

Your surgeon will discuss the risks that apply to your individual operation, taking into account your age, lung and heart function, smoking history, and other medical conditions.

Adjuvant and Neoadjuvant Treatment

Treatment after surgery (adjuvant)

• Chemotherapy is commonly recommended after surgery for stage II and many stage III NSCLC cases, and may be offered in some larger stage I tumours.
• Targeted therapy. For tumours that carry certain genetic changes — for example, EGFR mutations or ALK rearrangements — oral targeted drugs given after surgery have been shown in clinical trials to reduce the risk of the cancer returning.
• Immunotherapy. Drugs that activate the immune system against cancer are now part of post-surgical treatment for many patients, often after chemotherapy.
• Radiation therapy may be considered if the surgical margins were not clear or if there was significant lymph node involvement.

Treatment before surgery (neoadjuvant)

Increasingly, chemotherapy combined with immunotherapy is given before surgery for selected stage II and III NSCLC. This approach can shrink the tumour, make the operation more complete, and treat microscopic disease early. Major guidelines now describe perioperative chemo-immunotherapy as an established option in suitable patients.

Whether and which of these treatments applies to you is decided with your medical and radiation oncologists, taking your tumour’s biology and your overall health into account.

Life After Lung Cancer Surgery

After surgery, life slowly settles into a new routine. Several themes are common.

Breathing and exercise

For most patients who have a lobectomy or smaller resection, day-to-day breathing returns close to baseline within a few months. Climbing stairs and walking briskly may feel harder initially. Pulmonary rehabilitation — a structured programme of supervised exercise and breathing training — can be very helpful, particularly after pneumonectomy or for patients with pre-existing lung disease.

Returning to work and activity

Return to work depends on the type of work, the operation, and your recovery. Office work may be possible within four to six weeks; physically demanding work may require longer, sometimes two to three months. Driving usually resumes once you are off strong pain medicines and can move comfortably; check with your surgeon.

Travel and flying

Most patients can fly again a few weeks after surgery, once any air leak has fully resolved, but timing should be confirmed with your team. Long-haul travel raises the risk of blood clots in the legs; walking regularly during the flight, staying hydrated, and wearing compression stockings help.

Emotional adjustment

A lung cancer diagnosis and major surgery affect emotional health, not just physical health. Anxiety about recurrence is common, particularly around scan dates — sometimes called “scanxiety”. Talking to a counsellor, a patient support group, or a mental health professional can be very useful. Family members are often affected too.

Smoking

If you smoked before diagnosis, stopping permanently is one of the single most important steps to reduce the risk of further lung damage, recurrence, and second cancers. Most cancer centres provide support for stopping smoking.

Follow-up and surveillance

After curative surgery, regular follow-up is essential. Major cancer guidelines suggest a clinic visit and CT scan of the chest every six months for the first two to three years, then yearly afterwards, with the schedule adjusted to your stage and treatment. Follow-up appointments check for:

• Signs of cancer recurrence in the chest or elsewhere
• New, second primary lung cancers
• Late effects of treatment
• Lung function and general health

If new symptoms develop between visits — persistent new cough, unexplained weight loss, new bone or back pain, headaches, neurological symptoms — contact your team rather than waiting for the next scheduled appointment.

Survival and Outlook

Outcomes after lung cancer surgery depend strongly on the stage at which the cancer was found, the type of cancer, its molecular profile, how completely it was removed, and the patient’s overall health. Major cancer society data and clinical studies consistently show:

• The earlier the stage, the better the outlook. Five-year survival for surgically treated stage I NSCLC is substantially higher than for later stages.
• Complete (R0) resection with adequate lymph node assessment is a strong predictor of better long-term outcomes.
• Adjuvant treatment in selected stages further improves the chance of long-term disease control.
• Modern targeted therapies and immunotherapies have meaningfully extended survival, even in advanced disease.

Specific survival numbers vary between centres and populations, and the figures most often quoted come from large registries. Your own surgeon and oncologist are best placed to discuss what the published data mean for your particular stage and situation. Two patients with the “same stage” can have meaningfully different outlooks once tumour biology, molecular markers, and overall health are taken into account.

Frequently Asked Questions

Will I be able to breathe normally after surgery?

Most patients who have a lobectomy or smaller resection are able to carry out their usual daily activities once they have recovered. Breathlessness on heavy exertion is common in the first months and improves. After pneumonectomy, breathlessness on exertion is more noticeable and often permanent, though many patients still manage a good quality of life.

How long will I be in hospital?

For VATS or robotic lobectomy, around three to five days is typical. Open thoracotomy and pneumonectomy generally require longer. The chest drain often dictates the length of stay.

How painful is the surgery?

There is pain after the operation, particularly with breathing, coughing, and movement. Modern pain control — epidural, nerve blocks, and a combination of medicines — manages it well in most cases. Pain is usually most noticeable in the first one to two weeks and gradually settles.

Will I have a large scar?

VATS and robotic surgery leave several small scars, usually a few centimetres each. Open thoracotomy leaves a longer curved scar along the side of the chest. Scars fade over months.

When can I drive again?

Usually when you are off strong opioid pain medicines, can move freely enough to look over your shoulder, and can comfortably perform an emergency stop. Most patients reach this point within a few weeks of minimally invasive surgery. Your surgeon will advise based on your situation.

Will I need chemotherapy or other treatment after surgery?

It depends on the final stage and molecular features of the tumour. Many patients with stage I disease need no further treatment. Patients with stage II or III disease, and those with certain genetic changes, are often offered chemotherapy, targeted therapy, or immunotherapy after surgery.

Can lung cancer come back after surgery?

Yes. Even after complete removal, lung cancer can return in the lung, the chest, or other parts of the body, particularly in the first few years. This is why regular follow-up scans are important, and why adjuvant treatment is offered in higher-stage disease.

Is minimally invasive surgery as effective as open surgery?

For suitable early-stage lung cancers, large studies have shown that VATS and robotic approaches achieve similar long-term cancer outcomes to open surgery, with less pain and faster recovery. For complex or large tumours, open surgery may still be the best option. The right approach is decided by your surgeon based on your scans and overall situation.

Do I need to stop smoking before surgery?

Stopping smoking before surgery has been clearly shown to reduce the risk of complications. Even a few weeks of not smoking before the operation helps. Continuing to abstain after surgery reduces the risk of further lung damage and second cancers.

What if my lung function is borderline?

Your team may recommend a smaller, lung-sparing operation (segmentectomy or wedge resection), a course of pulmonary rehabilitation before surgery, or, in some cases, a non-surgical treatment such as stereotactic body radiation therapy. This is a clinical decision based on detailed lung function testing and exercise assessment.

Conclusion

Lung cancer surgery is a major operation, and current guidelines from leading cancer societies describe it as the cornerstone of curative treatment for early-stage non-small cell lung cancer and for selected locally advanced cases. Modern thoracic surgery has moved decisively toward minimally invasive approaches — VATS and robotic-assisted surgery — and toward lung-sparing operations where these are safe, with the aim of removing the cancer completely while preserving as much breathing capacity and quality of life as possible.

The journey involves more than the operation itself: careful staging, fitness optimisation, the surgery, structured recovery, and, in many cases, additional treatment with chemotherapy, targeted therapy, or immunotherapy. Long-term follow-up is essential to watch for recurrence and to support healthy living after cancer.

The decisions along the way — which operation, which approach, which adjuvant treatment, what follow-up — are made together with a multidisciplinary team that knows your case in detail. Understanding the medical landscape helps you take part in those conversations and plan the next phase of your care with clarity.